Treatment of thromboembolism in IBD: More questions than answers

Inflammatory Bowel Diseases

Volumn 18, Issue 1, 2012, Pages 172-173

  Nguyen, Geoffrey C ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CATHETER DIRECTED THROMBOLYSIS; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; EDITORIAL; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEMATOCHEZIA; HUMAN; LUNG EMBOLISM; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CATHETER ABLATION; HUMANS; INFLAMMATORY BOWEL DISEASES; THROMBOEMBOLISM; THROMBOLYTIC THERAPY;

EID: 83455257875     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21624     Document Type: Editorial

References (14)

1. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001; 85: 430-434. (Pubitemid 32233013)
2. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004; 53: 542-548. (Pubitemid 38372979)
3. Solem CA, Loftus EV, Tremaine WJ, et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004; 99: 97-101. (Pubitemid 38679109)
4. Talbot RW, Heppell J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986; 61: 140-145. (Pubitemid 16127025)
5. Shen J, Ran ZH, Tong JL, et al. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 653-663. (Pubitemid 47246205)
6. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010; 139: 779-787.
7. Fiumara K, Kucher N, Fanikos J, et al. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 2006; 97: 127-129. (Pubitemid 41828136)
8. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. The UKEP Study Research Group. Eur Heart J. 1987; 8: 2-10.
9. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 1999; 211: 39-49. (Pubitemid 29161732)
10. Dong B, Jirong Y, Liu G, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2006; 19: CD004437.
11. Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol. 2002; 40: 1660-1667. (Pubitemid 35253645)
12. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. 2008; 133: 454S-545S. (Pubitemid 351892971)
13. Novacek G, Vogelsang H, Genser D, et al. Changes in blood rheology caused by Crohn's disease. Eur J Gastroenterol Hepatol. 1996; 8: 1089-1093. (Pubitemid 26383867)
14. Grainge MJ, West J, Card TR,. Venous thromboembolism during active disease and remission in inflammatory bowel disease. Lancet. 2010; 375: 657-663.